News

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of

The companies did not disclose the value of the expanded collaboration, which features a new, three-year research partnership. Under the partnership, the companies will develop cognitive technologies to

The joint project will see Fimbrion and the Discovery Partnerships with Academia (DPAc) team at GSK focus on the preclinical development of a class of mannose-containing small molecule

Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. John Curnutte, M.D. Ph.D., executive vice president, research and development at Portola, said:

The I-SPY 2 TRIAL, sponsored by QuantumLeap Healthcare Collaborative (QLHC), is a standing phase 2 randomized, controlled, multicenter study with an innovative adaptive design aimed to rapidly screen

Pablo Lapuerta, M.D., Lexicon’s executive vice president and chief medical officer, said: "The inTandem4 Phase 2 dose-ranging study represents the first of three clinical trials of sotagliflozin that

Debiopharm completed a double-blind randomized phase II study evaluating the efficacy of two different doses of intravenous and oral Debio 1450 compared to intravenous vancomycin and oral linezolid

The phase III SOLO-2 trial randomized 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least two prior lines of platinum-based chemotherapy. It showed

The company signed an agreement with the US Food and Drug Administration (FDA) regarding the trial’s design. The phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS